Detail akcie Shattuck Labs Rg online

Business Summary: Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Shattuck Labs Inc revenues decreased 83% to $1M. Net loss decreased 36% to $36.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Pharmaceutical Preparations segment loss decrease of 37% to $38.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.12 to -$0.65.